Jorge Santos da Silva, Chief Executive Officer of MoonLake Immunotherapeutics (MLTX), said: “In 2024, we successfully advanced to Phase 3 clinical trials across several potential blockbuster indications with the launch of our Phase 3 VELA and Phase 3 IZAR programs, leaving us strongly positioned ahead of a data-rich 2025. With seven ongoing Phase 2 and Phase 3 trials, plus other ancillary trials running, this has been a time dedicated to execution, as we previously announced. With our pivotal HS data expected as of mid-2025, our focus is firmly on bringing this innovation to patients as we move towards commercialization.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLTX:
- Closing Bell Movers: JB Hunt down 9% after Q4 earnings miss
- MoonLake Immunotherapeutics upgraded to Buy from Neutral at Goldman Sachs
- Goldman upgrades MoonLake to Buy into hidradenitis suppurativa data
- MoonLake Immunotherapeutics price target raised to $81 from $71 at BTIG
- MoonLake Immunotherapeutics initiates three new clinical trials